Abstract
The quantifiable costs associated with human disease and illness are typically categorized into two unique components, including direct and indirect costs. Direct costs usually represent the costs associated with medical resource utilization, which include the consumption of in-patient, out-patient, and pharmaceutical services within the health care delivery system. The term indirect costs has come to be defined as the expenses incurred from the cessation or reduction of work productivity as a result of the morbidity and mortality associated with a given disease. Indirect costs typically consist of work loss, worker replacement, and reduced productivity from illness and disease. These losses are typically valued from either societal, individual, or employer perspectives (1,2).
Keywords
- Indirect Cost
- Leisure Time
- Societal Perspective
- National Health Interview Survey
- Work Loss
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60: 429–462.
Eisenberg JM. Clinical Economics- A guide to the economic analysis of clinical practices. JAMA 1989; 262: 2879–2886.
Herrin J, Cangialose CB, Boccuzzi SJ, et al. Household income losses associated with ischaemic heart disease for US employees. Pharmacoeconomics 2000; 3: 305–314.
Koopmanschap MA, Rutten FF. Indirect costs in economic studies: confronting the confusion. Pharmacroeconomics 1993; 4: 446–454.
American Heart Association. 2001 Heart and Stroke Statistical Update. American Heart Association, Dallas, TX, 2000.
Burton WN, Conti DJ, Chen CY, et al. The economic burden of lost productivity due to migraine headache: a specific worksite analysis. J Occup Environ Med 2002; 44: 523–529.
Bartell A, Taubman P. Health and labor market success: the role of various diseases. Rev Econ Stat 1979; 61: 1–8.
Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature. Int J Technol Assess Health Care 1998; 14: 799–808.
Drummond M. Cost-of-illness, a major headache? Pharmacoeconomics 2992; 2: 1–4.
Weinstein MC, Siegel JE, Garber AM, et al. Productivity costs, time costs and health related quality of life: a response to the Erasmus Group. Health Econ 1997; 6: 505–510.
Berger ML, Murray JF, Xu J, Pauly M. Alternative valuations of work loss and productivity. J Occup Environ Med 2001; 43: 18–24.
Berdt ER, Finklestein SN, Greenberg PE, et al. Workplace performance effects from chronic depression and its treatment. J Health Econ 1998; 17: 511–535.
Burton WN, Conti DJ, Chen CY, et al. The role of health risk factors and disease on worker productivity. J Occup Environ Med 1999; 41: 863–877.
Goetzel RZ, Guindon AM, Turshen IJ, Ozminkowski RJ. Health and productivity management: establishing key performance measures, benchmarks and best practices. J Occup Environ Med 2001; 43: 10–17.
Stern S. Measuring the effect of disability on labor force participation. J Human Resources 1989; 24: 360–394.
Hodgson TA. Costs of illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomics 1994; 6: 536–552.
Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature. Int J Technol Assess Health Care 1998; 14: 799–808.
Rizzo JA, Abbott TA, Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Econ 1996; 5: 249–265.
Rice DP. Estimating the cost of illness. Am J Public Health 1967; 57: 424–440.
Cooper B, Rice DP. The economic cost of illness revisited. Soc Sec Bull 1976; 39: 21–36.
Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoenoomics 1998; 13: 1–7.
Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity cost measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ 1997; 6: 253–259.
Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–189.
Koopmanschap MA, van Ineveld BM. Toward a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 1005–1010.
Koopmanschap MA, Rutten FFH. The impact of indirect costs on outcomes of health care programs. Health Econ 1994; 3: 385–393.
Koopmanschap MA, Rutten FFH. The consequence of production loss or increased costs of production. Med Care 1996; 34: 12.
Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10: 460–466.
Correspondance. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13: 563–569.
Johannesson M, Karlsson G. The friction cost method: a comment. J Health Econ 1997; 16: 249–255.
Guico-Pabia CJ, Murray JF, Teutsch SM, et al. Indirect costs of ischemic heart disease to employers. Am J Manag Care 2001; 7: 27–34.
Sagmeister M, Gessner U, Horisberger B, Gutzwiller F. An economic analysis of ischaemic heart disease in Switzerland. Eur Heart J 1997; 18: 1102–1109.
Pestana JAX, Steyn K, Leiman A, Hartzenberg GM. The direct and indirect costs of cardiovascular disease in South Africa in 1991. S A Med J 1996; 86: 679–684.
Zethraeus N, Molin T, Henriksson P, Jonsson B. Costs of coronary heart disease and stoke: the case of Sweden. J Intern Med 1999; 246: 151–159.
Evans CJ, Crawford B. Data collection methods in prospective economic evaluation: how accurate are the results. Value in Health 2000; 3: 277–286.
Greenberg PE, Birnbaum HG, Kessler RC, et al. Impact of illness and its treatment on workplace costs: regulatory and measurement issues. J Occup Environ Med 2001; 43: 56–63.
Canadian Coordinating Office for Health Technology assessment. A Guidance Document for the Costing Process. Canadian Coordinating Office for Technology Assessment, Ottawa, Canada, 1996.
Canadian Coordinating Office for Health Technology assessment. Guidelines for Economic Evaluation of Pharmaceuticals: Canada, 2nd ed. Canadian Coordinating Office for Technology Assessment, Ottawa, Canada, 1997.
Commonwealth Department of Human Services and Health, Australia. Australian Guidelines. Australian Government Publishing Service, Canberra, Australia, 1995.
Riteco JA, Heij LJ, Luijn JC, et al. Richtlijnen Voor farmaco-economisch onderzoek. Amstelveen: College voor zorgverzekeringen, 1999.
Siegel JE, Torrance GW, Russel LB, et al. and the Members on the Panel of Cost Effectiveness in Health and Medicine. Pharamcoeconomics 1997; 11: 159–168.
Botman SL, Jack SS. Combining National Health Interview survey datasets: issues and approaches. Statistics in Med 1995; 14: 669–677.
National Death Index, Division of Vital Statistics, National Center for Health Statistics. (http://www.cdc.gov) accessed 2002, Hyattsville, MD.
United States Bureau of Labor Statistics. (http://www.bls.gov) accessed 2002, Washington, DC.
United States Department of Commerce. (http://www.commerce.gov) accessed 2002, Washington, DC.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Boccuzzi, S.J. (2003). Indirect Health Care Costs. In: Weintraub, W.S. (eds) Cardiovascular Health Care Economics. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-398-9_5
Download citation
DOI: https://doi.org/10.1007/978-1-59259-398-9_5
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9784-7
Online ISBN: 978-1-59259-398-9
eBook Packages: Springer Book Archive